Drugs / SAR444836
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05972629 | Aug 2023 → Apr 2030 expected | phenylketonuria | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR444836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05972629 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated virus (AAV) vector-mediated gene transfer” NCT05972629 ↗ |
| Route | Intravenous | “Participants will receive a one-time intravenous (IV) administration of SAR444836.” NCT05972629 ↗ |
| Target | PAH | “gene transfer of human phenylalanine hydroxylase (PAH)” NCT05972629 ↗ |